Preparation and in vivo and ex vivo studies of sirolimus nano-in-situ gel ophthalmic formulation.

J Nanobiotechnology · 2024 · PMC11253443 · PMID 39014353

Europe PMC DOI

hedged sentence

0.0100

closest p · 0.2× alpha

0.0100

boldest claim

The sentences

highly significantp < 0.01actually significant

5 (G) demonstrated a higher cumulative release rate of SR-SUS compared to SR-SUS-ISG, showing a significant difference ( p < 0.05), which became highly significant ( p < 0.01) after 6 h of release.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.